Committee header
Active cycles
Panel 2 • Finance overview
Committee finance snapshot
Scope: All time
Money over time
Panel 3 • Money structure snapshot
Money structure snapshot
$5,000+ is the largest bucket at 100% of total raised.
Dominant category: Operations at 89.9% of spending.
Donor count
57
Contributions
212
Median
$39,171
Average
$520,439
Funding distribution
$5,000+
Count: 210
Share: 100%
Amount: $110,326,346
$1,000 - $4,999
Count: 2
Share: 0%
Amount: $6,814
Panel 5 • Financial evidence
Filings workspace
Filing history and transaction-level evidence moved to a dedicated page.
Open filings pageCommittee header
Active cycles
Panel 2 • Finance overview
Committee finance snapshot
Scope: All time
Money over time
Panel 3 • Money structure snapshot
Money structure snapshot
$5,000+ is the largest bucket at 100% of total raised.
Dominant category: Operations at 89.9% of spending.
Donor count
57
Contributions
212
Median
$39,171
Average
$520,439
Funding distribution
$5,000+
Count: 210
Share: 100%
Amount: $110,326,346
$1,000 - $4,999
Count: 2
Share: 0%
Amount: $6,814
Panel 5 • Financial evidence
Filings workspace
Filing history and transaction-level evidence moved to a dedicated page.
Open filings page| Contribution bucket |
|---|
| Count |
|---|
| Amount |
|---|
| Share of raised |
|---|
| $5,000+ | 210 | $110,326,346 | 100% |
| $1,000 - $4,999 | 2 | $6,814 | 0% |
Spending categories
Operations
Amount: $100,591,773
Share: 89.9%
Media
Amount: $5,772,537
Share: 5.2%
Consulting
Amount: $5,112,780
Share: 4.6%
Field
Amount: $428,413
Share: 0.4%
| Contribution bucket |
|---|
| Count |
|---|
| Amount |
|---|
| Share of raised |
|---|
| $5,000+ | 210 | $110,326,346 | 100% |
| $1,000 - $4,999 | 2 | $6,814 | 0% |
Spending categories
Operations
Amount: $100,591,773
Share: 89.9%
Media
Amount: $5,772,537
Share: 5.2%
Consulting
Amount: $5,112,780
Share: 4.6%
Field
Amount: $428,413
Share: 0.4%
Panel 4 • Top donors
Top donors
| Donor | Total | Share* | Count | Last |
|---|---|---|---|---|
| MERCK & CO., INC. | $9,432,295 | 8.5% | 4 | Mar 5, 2021 |
| PFIZER, INC. | $9,420,395 | 8.5% | 4 | Oct 19, 2016 |
| JOHNSON & JOHNSON | $9,301,646 | 8.4% | 4 | Oct 19, 2016 |
| AMGEN INC. | $7,685,422 | 7% | 7 | Feb 20, 2020 |
| ABBVIE INC. | $6,872,073 | 6.2% | 5 | Apr 13, 2020 |
| SANOFI-AVENTIS U.S. LLC | $6,745,045 | 6.1% | 6 | Mar 5, 2021 |
| ASTRAZENECA PHARMACEUTICALS LP | $6,080,535 | 5.5% | 4 | Oct 19, 2016 |
| ALLERGAN USA, INC. | $5,079,332 | 4.6% | 4 | Oct 19, 2016 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $4,752,402 | 4.3% | 5 | Jun 17, 2021 |
| ELI LILLY AND COMPANY | $4,540,194 | 4.1% | 6 | Mar 5, 2021 |
| BRISTOL-MYERS SQUIBB COMPANY | $4,539,530 | 4.1% | 4 | Apr 29, 2021 |
| GLAXO SMITH KLINE | $4,528,527 | 4.1% | 4 | Oct 19, 2016 |
| BIOGEN | $4,503,390 | 4.1% | 4 | Oct 19, 2016 |
| GILEAD SCIENCES, INC MAJOR DONOR #496265 | $4,000,000 | 3.6% | 1 | Apr 14, 2016 |
| NOVO NORDISK INC. | $3,538,000 | 3.2% | 3 | Aug 9, 2016 |
| GENENTECH, INC. | $3,000,000 | 2.7% | 2 | Aug 18, 2016 |
| BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | $2,028,690 | 1.8% | 4 | Oct 19, 2016 |
| ASTELLAS PHARMA US, INC. | $1,794,781 | 1.6% | 6 | Mar 5, 2021 |
| TAKEDA PHARMACEUTICALS U.S.A., INC. | $1,718,723 | 1.6% | 6 | Jun 17, 2021 |
| PURDUE PHARMA L.P. | $1,586,057 | 1.4% | 3 | Oct 19, 2016 |
| OTSUKA AMERICA, INC. (OAI) | $1,421,955 | 1.3% | 4 | Oct 19, 2016 |
| BAYER CORPORATION | $1,388,200 | 1.3% | 4 | Feb 20, 2020 |
| CELGENE CORPORATION | $1,376,000 | 1.2% | 3 | Aug 19, 2016 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $1,001,475 | 0.9% | 16 | Sep 13, 2018 |
| MALLINCKRODT PHARMACEUTICALS | $691,581 | 0.6% | 3 | Oct 19, 2016 |
* Share is percent of committee total raised in the selected scope. Page rows are a subset and typically do not sum to 100%.
Panel 4 • Top donors
Top donors
| Donor | Total | Share* | Count | Last |
|---|---|---|---|---|
| MERCK & CO., INC. | $9,432,295 | 8.5% | 4 | Mar 5, 2021 |
| PFIZER, INC. | $9,420,395 | 8.5% | 4 | Oct 19, 2016 |
| JOHNSON & JOHNSON | $9,301,646 | 8.4% | 4 | Oct 19, 2016 |
| AMGEN INC. | $7,685,422 | 7% | 7 | Feb 20, 2020 |
| ABBVIE INC. | $6,872,073 | 6.2% | 5 | Apr 13, 2020 |
| SANOFI-AVENTIS U.S. LLC | $6,745,045 | 6.1% | 6 | Mar 5, 2021 |
| ASTRAZENECA PHARMACEUTICALS LP | $6,080,535 | 5.5% | 4 | Oct 19, 2016 |
| ALLERGAN USA, INC. | $5,079,332 | 4.6% | 4 | Oct 19, 2016 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $4,752,402 | 4.3% | 5 | Jun 17, 2021 |
| ELI LILLY AND COMPANY | $4,540,194 | 4.1% | 6 | Mar 5, 2021 |
| BRISTOL-MYERS SQUIBB COMPANY | $4,539,530 | 4.1% | 4 | Apr 29, 2021 |
| GLAXO SMITH KLINE | $4,528,527 | 4.1% | 4 | Oct 19, 2016 |
| BIOGEN | $4,503,390 | 4.1% | 4 | Oct 19, 2016 |
| GILEAD SCIENCES, INC MAJOR DONOR #496265 | $4,000,000 | 3.6% | 1 | Apr 14, 2016 |
| NOVO NORDISK INC. | $3,538,000 | 3.2% | 3 | Aug 9, 2016 |
| GENENTECH, INC. | $3,000,000 | 2.7% | 2 | Aug 18, 2016 |
| BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | $2,028,690 | 1.8% | 4 | Oct 19, 2016 |
| ASTELLAS PHARMA US, INC. | $1,794,781 | 1.6% | 6 | Mar 5, 2021 |
| TAKEDA PHARMACEUTICALS U.S.A., INC. | $1,718,723 | 1.6% | 6 | Jun 17, 2021 |
| PURDUE PHARMA L.P. | $1,586,057 | 1.4% | 3 | Oct 19, 2016 |
| OTSUKA AMERICA, INC. (OAI) | $1,421,955 | 1.3% | 4 | Oct 19, 2016 |
| BAYER CORPORATION | $1,388,200 | 1.3% | 4 | Feb 20, 2020 |
| CELGENE CORPORATION | $1,376,000 | 1.2% | 3 | Aug 19, 2016 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $1,001,475 | 0.9% | 16 | Sep 13, 2018 |
| MALLINCKRODT PHARMACEUTICALS | $691,581 | 0.6% | 3 | Oct 19, 2016 |
* Share is percent of committee total raised in the selected scope. Page rows are a subset and typically do not sum to 100%.